Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

RegulatoryapprovedOCU400Positive

AI Analysis

Summary

Ocugen's OCU400 gene therapy for retinitis pigmentosa received provisional approval and priority designation from The Bahamas regulatory authority (LARTA Board). The company plans to initiate patient treatment through an expanded access program within 90 days of receiving full approval.

Outcome Details

Provisional approval and priority designation granted by LARTA Board in The Bahamas; patient treatment expected within 90 days following full approval

Importance:6/10

Sentiment:

0.75

gene therapyregulatory approvalretinitis pigmentosaBahamasLARTAexpanded access program

Related Companies

$OCGN

Read the original article

Published by GlobeNewswire Clinical Studies on September 25, 2026 11:02 AM

Read Original